

Uganda

Population 2015

39 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	5.5 (3.3–8.3)	14 (8.5–21)
Mortality (HIV+TB only)	6.4 (1.7–14)	16 (4.3–36)
Incidence (includes HIV+TB)	79 (47–119)	202 (120–304)
Incidence (HIV+TB only)	26 (16–37)	66 (42–94)
Incidence (MDR/RR-TB)**	1.9 (1–2.8)	4.9 (2.6–7.2)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	3.2 (1.2–5.3)	23 (5.8–41)	27 (7–46)
Males	3.8 (2.2–5.3)	48 (32–64)	52 (34–70)
Total	7 (4.5–9.5)	72 (52–91)	79 (47–119)

TB case notifications, 2015	
Total cases notified	43 736
Total new and relapse	41 912
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	91%
- % bacteriologically confirmed among pulmonary	71%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	53% (35–89)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.16 (0.07–0.31)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	17 642	42%
- on antiretroviral therapy	15 448	88%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 000 (660–1 400)
Estimated % of TB cases with MDR/RR-TB	1.6% (0.78–2.4)	12% (5.9–18)	
% notified tested for rifampicin resistance	8%	37%	6 827
MDR/RR-TB cases tested for resistance to second-line drugs			252
Laboratory-confirmed cases		MDR/RR-TB: 252, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 253, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	75%	43 628
Previously treated cases, excluding relapse, registered in 2014	67%	2 438
HIV-positive TB cases, all types, registered in 2014	73%	16 670
MDR/RR-TB cases started on second-line treatment in 2013	73%	214
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	38
Funding source: 4% domestic, 78% international, 19% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically